ArticleNature communications2021
Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Extensive-stage small cell esophageal carcinoma: a retrospective analysis of treatment modalities.BMC cancer · 2026Article
- Sequential Esophageal Squamous Cell Carcinoma and Small Cell Carcinoma Following Prior Nissen Fundoplication.Cureus · 2026Article
- Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026Review
- Treatment strategies for small cell carcinoma of the esophagus: comparative analysis of multimodal regimens in two independent real-world cohorts.The oncologist · 2026Article
- Cell-cycle targeted cancer therapy: clinical advances, biological gaps, and the emergence of selective CDK4 inhibitors.Journal of hematology & oncology · 2026Review
- Adenocarcinoma admixed with neuroendocrine carcinoma of the cervix: a clinicopathological diagnostic study and molecular features.Diagnostic pathology · 2026Article
- Pattern of Lymph Node Metastases and Recurrence in Thoracic Small Cell Esophageal Carcinoma: A Single-Institution Experience.Annals of surgical oncology · 2026Article
- Proteogenomic Characterization Reveals Subtype-Specific Therapeutic Potential for HER2-Low Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma.Oncology letters · 2026Article
- Multidimensional Regulatory Network ofOncology research · 2026Review
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Differentiating well-differentiated neuroendocrine tumors grade 3 from poorly differentiated neuroendocrine carcinomas and adenocarcinoma with neuroendocrine differentiation: a comprehensive review.Virchows Archiv : an international journal of pathology · 2026Review
- Unraveling the characteristics of early esophageal neuroendocrine carcinoma using multi-model endoscopy: A retrospective study of serial cases.World journal of gastrointestinal oncology · 2025Article
- Article
- Multi-omic-based classification for identifying optimal neoadjuvant treatment strategies for high-risk early-stage breast cancer.Science China. Life sciences · 2025Article
- Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis.Molecular cancer · 2025Article
- A novel risk stratification system for primary small-cell carcinoma of the esophagus: indication for prognostication and staging.Journal of the National Cancer Center · 2025Article
- NSE and ProGRP Are Promising Markers for Diagnosis, Efficacy Evaluation, Follow-Up Monitoring, and Prognosis of Small Cell Esophageal Carcinoma.Thoracic cancer · 2025Article
- Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus.Frontiers in bioinformatics · 2025Article
- The impact of immunotherapy on the prognosis of small cell carcinoma of the esophagus: a propensity score-matched analysis of a retrospective study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary small cell carcinoma of the esophagus (PSCCE) is a lethal neuroendocrine carcinoma. Previous studies proposed a genetic similarity between PSCCE and esophageal squamous cell carcinoma (ESCC) but provided little evidence for differences in clinical course and neuroendocrine differentiation. We perform whole-exome sequencing, RNA sequencing and immunohistochemistry profiling on 46 PSCCE cases. Integrated analyses enable the discovery of multiple mechanisms of RB1 disruption in 98% (45/46) of cases. The transcriptomic landscape of PSCCE closely resembles small cell lung cancer (SCLC) but differs from ESCC or esophageal adenocarcinoma (EAC). Distinct gene expression patterns regulated by ASCL1 and NEUROD1 define two molecular subtypes, PSCCE-A and PSCCE-N, which are highly similar to SCLC subtypes. A T cell excluded phenotype is widely observed in PSCCE. In conclusion, PSCCE has genomic alterations, transcriptome features and molecular subtyping highly similar to SCLC but distinct from ESCC or EAC. These observations are relevant to oncogenesis mechanisms and therapeutic vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.